drugset / Trial / NCT02945007

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

NCT02945007

Phase 1 Completed 82 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the relative bioavailability of 1 to 3 concept formulations of JNJ-53718678 compared to the currently existing oral solution, and to assess the effect of food on the bioavailability of 1 to 3 oral concept formulations of JNJ-53718678 when administered as a single oral dose of 500 milligram (mg) in healthy adult participants.

Timeline

Start
2016-11-08
Primary completion
2020-01-16
Completion
2020-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified 500 mg Oral

Indications

No indication recorded.